IP Library Granted Patent US 8,217,174
Granted Patent B2
US 8,217,174 · App. 12/518,213 · Granted Jul 10, 2012

Method of preparing montelukast and intermediates used therein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,217,174
App. No.
12/518,213
Granted
Jul 10, 2012
Kind
B2
Abstract

The present invention relates to a method for preparing montelukast, an inhibitor against leukotrienes, and an intermediate used therein. According to the inventive method, high-purity montelukast or its sodium salt can be prepared in a high yield.

Claims (22)

1. A method for preparing montelukast or its sodium salt of formula (I) comprising the steps of:

(a) allowing a halophosphate compound of formula (V) to react with the diol compound of formula (IV) in a solvent in the presence of a base to produce a phosphate compound of formula (III); and

(b) coupling the phosphate compound of formula (III) with a thiocarboxylic acid compound of formula (II) in a solvent in the presence of a base:

wherein,

R is H or Na;

R 1 is H, methyl, or ethyl;

R 2 is methyl, ethyl, or phenyl;

X is halogen;

Y is sulfur or oxygen.

2. The method of claim 1 , wherein the base used in step (a) is selected from the group consisting of pyridine, triethylamine, tributylamine, diisopropylethylamine, methylpiperidine, and a mixture thereof.

3. The method of claim 2 , wherein the base is triethylamine.

4. The method of claim 1 , wherein the amount of the halophosphate compound of formula (V) used in step (a) is one equivalent or more based on the diol compound of formula (IV).

5. The method of claim 1 , wherein 4-dimethylaminopyridine or 4-pyrrolidinopyridine is further used as a catalyst in step (a).

6. The method of claim 1 , wherein the halophosphate compound is the compound of formula (V) in which X is Cl, Y is O, and R 2 is phenyl.

7. The method of claim 1 , wherein the solvent used in step (a) is selected from the group consisting of benzene, toluene, acetonitrile, tetrahydrofuran, methylene chloride, chloroform, ethyl acetate, and a mixture thereof.

8. The method of claim 1 , wherein the base used in step (b) is selected from the group consisting of sodium hydroxide, sodium hydride, potassium t-butoxide, sodium methoxide, sodium ethoxide, triethylamine, pyridine, and a mixture thereof.

9. The method of claim 1 , wherein the solvent used in step (b) is selected from the group consisting of dimethylformamide, dimethylsulfoxide, acetonitrile, chloroform, methylene chloride, tetrahydrofuran, 1,4-dioxane, ethyl acetate, ethanol, methanol, and a mixture thereof.

10. The method of claim 9 , wherein the solvent is dimethylformamide.

11. A phosphate compound of formula (III):

wherein,

R 2 is methyl, ethyl, or phenyl;

Y is sulfur or oxygen.

Assignments (3)
CHANGE OF NAME Recorded Aug 3, 2012
From: HANMI HOLDINGS CO., LTD.
To: HANMI SCIENCE CO., LTD.
Reel/Frame 028722/0332 →
CHANGE OF NAME Recorded Jan 7, 2011
From: HANMI PHARM. CO., LTD.
To: HANMI HOLDINGS CO., LTD.
Reel/Frame 025599/0842 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2009
From: LEE, GWAN SUN; CHANG, YOUNG-KIL; LEE, JAEHEON; PARK, CHUL HYUN; PARK, EUN-JU; YOO, JAEHO
To: HANMI PHARM. CO., LTD.
Reel/Frame 022794/0732 →